Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients

NCT07197164 | Recruiting Phase 2 DMC

• 2 other identifiers: COVIDKIDNEY2024-519272-96-00
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Since the start of the COVID-19 pandemic, the approach to solid organ transplantation has evolved. Transplants using organs (excluding lungs) from COVID-19-positive donors have shown short-term safety, but there is limited data on recipients who are SARS-CoV-2 positive. Currently, kidney transplants in such recipients are delayed until symptoms resolve and a negative PCR is preferred, despite the risks of prolonged dialysis and increased cold ischemia time. Recent data from the Omicron era suggest that early antiviral treatment may reduce complications. Immunosuppressive therapy might even help mitigate severe inflammatory responses. The proposed study aims to show that kidney transplantation can be safely performed in asymptomatic or mildly symptomatic COVID-19-positive recipients who begin antiviral treatment (remdesivir) within 24 hours before transplant and continue for 10 days. This could reduce waiting times and improve outcomes. Remdesivir is an antiviral safe for use in patients with low kidney function, including those on dialysis or post-transplant, with minimal side effects. The hypothesis is that this treatment strategy can prevent progression to severe COVID-19 and allow safe transplantation

Conditions

COVID - 19; Renal Transplant; SARS CoV 2 Infection

Outcome Measures

Primary Outcomes (1)

• Number and proportion of participants who develop severe COVID-19 following kidney transplantation

  Primary estimates: Severe SARS-CoV-2 will be defined as: Hypoxemia (O2 sat \<94%), one or more compatible respiratory symptoms (fever, dyspnea, increased respiratory frequency \> 22, cough) AND new radiologic infiltrates compatible with COVID-19 in a chest X Ray, chest CT or ultrasound.

  to 28 days and 90 days post-transplant

Secondary Outcomes (7)

• Number of deaths (all causes mortality) at days 28 and 90 post-transplant

  at days 28 and 90 after transplant

• Time (days) to resolution and to recovery of all targeted symptoms through Day 28 and Day 90

  At day 28 and day 90

• Proportion of participants requiring extension of the hospitalization beyond POD10 (all cause and related to COVID-19)

  At day 28

• Proportion of participants with symptomatic rebound through day 28.

  At day 28

• To describe the clearance kinetics of SARS-CoV-2 infection in the post-transplant period

  At day 0, 5, 10, 14, 21 and 28

Study Arms (1)

Single Arm

EXPERIMENTAL

Single Arm with remdesivir

Drug: Remdesivir (RDV)

Interventions

Remdesivir (RDV) DRUG

Participants will receive their first dose of remdesivir also within the 24 (+/-12) hours prior to going to the operating room. Remdesivir doses will be 200 mg on day 1, followed by 100 mg daily from days 2 to 10, for a total of 10 days.

Also known as: Veklury

Single Arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 18 years-old
• Patients with end-stage kidney disease that are included on the local kidney transplant waiting list who get an offer of a compatible organ and, subsequently, have a transplant procedure scheduled in the next 24 (+/-) 12 hours, or patients with end-stage kidney disease that are planned to receive a non-cadaveric donor kidney transplant on the following 5 days.
• Have a positive SARS-CoV-2 nasopharyngeal PCR or RAT within 5 days prior to transplant surgery.
• Have previously received at least three SARS-CoV-2 vaccine doses, with a minimum time elapsed of 3 months since the last dose received.
• Are asymptomatic or have mild acute COVID-19 symptoms during the previous 5 days (headache, sore throat, cough, chest pain, nausea, diarrhea, fatigue, loss of smell or taste, myalgia) excluding fever in the previous 48 hours (\>38ºC) or shortness of breath.
• Post-menopausal or fertile females (females who are not surgically sterile or postmenopausal defined as amenorrhea for \>12 months) that agree to avoid pregnancy during the study. If sexually active fe-male; using highly effective contraceptive methods (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner\*) while on study treatment. All female volunteers must be willing to undergo urine pregnancy tests at time of enrollment.
• Having understood the information provided and capable of giving consent to participate in this trial by signing the Informed Consent document.

You may not qualify if:

• Pregnant or breastfeeding women, at time of enrollment
• Patients requiring supplementary oxygen at baseline or diagnosed with severe COPD or pulmonary fibrosis.
• Patients having any of the following at the screening period: i) O2 saturation below 94% on room air; ii) respiratory frequency of \> 30bpm; or iii) Xray showing new-onset pulmonary infiltrates suggesting COVID-19 pneumonia.
• Patients having fever (\>38ºC) in the last 48 hours or shortness of breath in the previous 5 days.
• Previous history of hypersensitivity, documented allergy or contraindications to receive remdesivir.
• ABO incompatible kidney transplant
• Desensitization therapy indicated as induction therapy for high immunological risk transplant with Donor Specific HLA Antibodies (DSA)
• Participants who receive different types of induction immunosuppression other than the standard induction protocols with lymphocyte- depleting agents (thymoglobulin or basiliximab).
• Suspected or confirmed concurrent active respiratory infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
• Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator.
• Prior participation in this trial.
• Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Sponsors & Collaborators

• Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia: lead
• Gilead Sciences: collaborator

Study Sites (1)

Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, 08916, Spain

RECRUITING

MeSH Terms

Conditions

COVID-19

Interventions

remdesivir

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Alba Romero Caballero, MD, MSc

CONTACT

+34 93 465 78 97; assaig@scienhub.org

Cristina Herrero Sánchez

CONTACT

info@scienhub.org

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Phase 2, proof of concept open-label, single-center, single- arm clinical trial

Study Record Dates

• First Submitted: September 25, 2025
• First Posted: September 29, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): February 28, 2027
• Last Updated: September 29, 2025

Record last verified: 2025-08

Locations

ES (1)